Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease

Andreea L. Turcu, Júlia Companys-Alemany, Matthew B. Phillips, Dhilon S. Patel, Christian Griñán-Ferré, M. Isabel Loza, José M. Brea, Belén Pérez, David Soto, Francesc X. Sureda, Maria G. Kurnikova, Jon W. Johnson, Mercè Pallàs, Santiago Vázquez*

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

23 Cites (Scopus)

Resum

Currently, of the few accessible symptomatic therapies for Alzheimer's disease (AD), memantine is the only N-methyl-d-aspartate receptor (NMDAR) blocker approved by the FDA. This work further explores a series of memantine analogs featuring a benzohomoadamantane scaffold. Most of the newly synthesized compounds block NMDARs in the micromolar range, but with lower potency than previously reported hit IIc, results that were supported by molecular dynamics simulations. Subsequently, electrophysiological studies with the more potent compounds allowed classification of IIc, a low micromolar, uncompetitive, voltage-dependent, NMDAR blocker, as a memantine-like compound. The excellent in vitro DMPK properties of IIc made it a promising candidate for in vivo studies in Caenorhabditis elegans (C. elegans) and in the 5XFAD mouse model of AD. Administration of IIc or memantine improved locomotion and rescues chemotaxis behavior in C. elegans. Furthermore, both compounds enhanced working memory in 5XFAD mice and modified NMDAR and CREB signaling, which may prevent synaptic dysfunction and modulate neurodegenerative progression.
Idioma originalAnglès
Número d’article114354
Nombre de pàgines28
RevistaEuropean Journal of Medicinal Chemistry
Volum236
DOIs
Estat de la publicacióPublicada - 5 de juny 2022

Paraules clau

  • Alzheimer's disease
  • Benzohomoadamantane
  • Caenorhabditis elegans
  • Electrophysiology
  • 5XFAD
  • Memantine analogs

Fingerprint

Navegar pels temes de recerca de 'Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease'. Junts formen un fingerprint únic.

Com citar-ho